Kiniksa Pharmaceuticals International, plc
78.52USD
+1.4300 (+1.85%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.32▼ | $0.32 | 2 | 2 |
| Next quarter | $0.29▼ | $0.31 | 2 | 2 |
| Current year | $1.16▼ | $1.2 | 1 | 2 |
| Next year | $1.62▼ | $1.76 | 1 | 2 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.29 | $0.3 | +0.02 (+5.3%) |
| 2026-03-31 | $0.16 | $0.27 | +0.11 (+68.8%) |
| 2025-12-31 | $0.4 | $0.17 | -0.23 (-57.3%) |
| 2025-09-30 | $0.37 | $0.23 | -0.14 (-37.3%) |
48 ratings from 12 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Goldman Sachs | Maintained | Buy | $75 $90 | Jul 30, 2026 |
| JP Morgan | Maintained | Overweight | $72 $107 | Jul 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $64 $98 | Jul 29, 2026 |
| Wedbush | Maintained | Outperform | $72 $99 | Jul 29, 2026 |
| Citigroup | Maintained | Buy | $60 $100 | Jul 29, 2026 |
| Goldman Sachs | Maintained | Buy | $60 $75 | Jul 23, 2026 |
| Wells Fargo | Maintained | Overweight | $57 $74 | Jul 13, 2026 |
| Wedbush | Maintained | Outperform | $59 $72 | Jun 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $62 $64 | Apr 29, 2026 |
| Citigroup | Maintained | Buy | $50 $60 | Apr 29, 2026 |
| Wedbush | Maintained | Outperform | $58 $59 | Apr 29, 2026 |
| Wells Fargo | Maintained | Overweight | $53 $57 | Apr 29, 2026 |
| Jefferies | Maintained | Buy | $58 $71 | Apr 28, 2026 |
| Wedbush | Maintained | Outperform | $53 $58 | Apr 16, 2026 |
| Wells Fargo | Maintained | Overweight | $50 $53 | Feb 25, 2026 |
| Wedbush | Maintained | Outperform | $50 $53 | Feb 25, 2026 |
| Canaccord Genuity | Initiated | Buy | $62 | Feb 19, 2026 |
| Wedbush | Maintained | Outperform | $48 $50 | Jan 13, 2026 |
| Goldman Sachs | Maintained | Buy | $45 $55 | Oct 29, 2025 |
| Citigroup | Maintained | Buy | $45 $50 | Oct 17, 2025 |
| Wedbush | Maintained | Outperform | $38 $44 | Oct 13, 2025 |
| TD Cowen | Initiated | Buy | $60 | Sep 29, 2025 |
| Wells Fargo | Maintained | Overweight | $42 $45 | Sep 25, 2025 |
| Jefferies | Maintained | Buy | $45 $54 | Jul 29, 2025 |
| Wells Fargo | Maintained | Overweight | $30 $42 | Jul 9, 2025 |
215 filings from 19 insiders · 38 buy / 12 sell over 6m
Officers and directors of KNSA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Megna Michael ROfficer, CHIEF ACCOUNTING OFFICER | Sell | 4.6k | $80.30 | $369k | Sep 3, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | ExerciseRestricted Share Unit | 2.5k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | ExerciseRestricted Share Unit | 1.6k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | ExerciseRestricted Share Unit | 1.7k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | ExerciseRestricted Share Unit | 2.5k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | GrantShare Option | 37.0k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | GrantRestricted Share Unit | 9.3k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | Tax | 4.0k | $79.28 | $318k | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | Exercise | 2.5k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | Exercise | 1.7k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | Exercise | 1.6k | — | — | Sep 1, 2026 |
| Moat RossOfficer, CHIEF OPERATING OFFICER | Exercise | 2.5k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | ExerciseRestricted Share Unit | 2.7k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | ExerciseRestricted Share Unit | 1.8k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | ExerciseRestricted Share Unit | 1.6k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | ExerciseRestricted Share Unit | 3.1k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | GrantShare Option | 31.1k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | GrantRestricted Share Unit | 7.8k | — | — | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | Tax | 4.4k | $79.28 | $349k | Sep 1, 2026 |
| Ragosa MarkOfficer, CHIEF FINANCIAL OFFICER | Exercise | 3.1k | — | — | Sep 1, 2026 |
No analyst notes on KNSA yet.
Analyst Ratings
8 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 7 | 0 | 0 | 0 | Buy1.88 |
| 1 mo ago | 1 | 7 | 0 | 0 | 0 | Buy1.88 |
| 2 mo ago | 1 | 7 | 0 | 0 | 0 | Buy1.88 |